Advertisement
Advertisement
PTCT
PTC Therapeutics, Inc.
60.97
USDSponsored
-2.52
-3.97%
Nov 16, 15:59 UTC -5
Closed
Pre-Market
60.37
-0.60
-0.98%
PTC Therapeutics, Inc. (PTCT) Earnings
PTCT Earnings Reports
Positive Surprise Ratio
PTCT beat 16 of 44 last estimates.
36%
Next Report
Date of Next Report
Feb 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
$336.93M
/$0.39
Implied change from Q3 26 (Revenue/ EPS)
-5.83%
/-162.90%
Implied change from Q4 25 (Revenue/ EPS)
+58.04%
/-123.35%
PTC Therapeutics, Inc. earnings per share and revenue
On Oct 29, 2026, PTCT reported earnings of -0.62 USD per share (EPS) for Q3 26, missing the estimate of 0.34 USD, resulting in a -277.96% surprise. Revenue reached 357.81 million, compared to an expected 312.53 million, with a 14.49% difference. The market reacted with a -6.97% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 9 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 336.93 million USD, implying an decrease of -162.90% EPS, and decrease of -5.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Enanta Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q4 26
Estimate
-$0.79
Actual
-$0.81
Surprise
-1.38%

Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%

Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%

Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+4.59%

Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
FAQ
What were PTC Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, PTC Therapeutics, Inc. reported EPS of -$0.62, missing estimates by -277.96%, and revenue of $357.81M, 14.49% above expectations.
How did the market react to PTC Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved down -6.97%, changed from $64.46 before the earnings release to $59.97 the day after.
When is PTC Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Feb 17, 2027.
What are the forecasts for PTC Therapeutics, Inc.'s next earnings report?
Based on 9
analysts, PTC Therapeutics, Inc. is expected to report EPS of $0.39 and revenue of $336.93M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.